I-02 Chayan Acharya
Population PK analysis of Pegaspargase in Japanese and non-Japanese patients with acute lymphoblastic leukemia
Wednesday 10:00-11:30 |
I-11 Marcus Baaz
Model-based Prediction of Progression-Free Survival for Combination Therapies in Oncology
Wednesday 10:00-11:30 |
I-12 Annabelle Ballesta
Quantitative Systems Pharmacology to Personalize Temozolomide-based Drug Combinations against Brain Tumors.
Wednesday 10:00-11:30 |
I-14 Imke Bartelink
Physiologically based pharmacokinetic modelling of the PSMA radioligand 18F-DCFPyL to predict the tissue distribution in patients with prostate cancer
Wednesday 10:00-11:30 |
I-16 Maxime Beaulieu
Simulation study to evaluate the identifiability of a non-linear multi-level joint model for the follow-up of patients with cancer
Wednesday 10:00-11:30 |
I-20 Elisa Borella
Elacestrant Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Elacestrant Dose Recommendations in Metastatic Breast Cancer (mBC) patients
Wednesday 10:00-11:30 |
I-21 Muriel Boulton
Exposure-Response (E-R) analysis of efficacy and safety of niraparib/abiraterone acetate combination in patients with metastatic castration-resistant prostate cancer
Wednesday 10:00-11:30 |
I-23 Aurore CARROT
Prognostic value of the modeled CA-125 kinetics parameter KELIM-PARP in patients with advanced ovarian cancer (AOC): analysis of the phase II BOLD study
Wednesday 10:00-11:30 |
I-24 Marc Cerou
Semi mechanistic joint modeling of tumor dynamics and PFS in advanced breast cancer: leveraging data from early amcenestrant phase I-II trials
Wednesday 10:00-11:30 |
I-28 Siak-Leng CHOI
Applying a quantitative system pharmacology (QSP) model to inform KRASG12C covalent inhibitors’ PK driver level needed for efficacy in patients with non-small cell lung cancer (NSCLC)
Wednesday 10:00-11:30 |
I-29 John Clements
Model-Based Meta-Analysis in Newly Diagnosed and Relapsed Refractory Multiple Myeloma to Support Outcome-Efficacy Translations and Extrapolations Across Lines of Therapy
Wednesday 10:00-11:30 |
I-38 Xiaoqing Fan
Pharmacokinetic and pharmacodynamic modeling of erythropoietin and romiplostim combination therapy in rats with chemotherapy-induced anemia and thrombocytopenia
Wednesday 10:00-11:30 |
I-40 Fernandez Teruel Carlos
Exposure–response analysis of safety and efficacy of capivasertib administered as monotherapy or in combination with fulvestrant
Wednesday 10:00-11:30 |
I-44 Glenn Gauderat
Mechanistic modelling of tumor uptake & interstitial receptor occupancy of PRS-344/S095012 using preclinical positron emission tomography data
Wednesday 10:00-11:30 |
I-46 Eva Germovsek
A semi-mechanistic model to describe preclinical tumour viral dynamics of an oncolytic virus
Wednesday 10:00-11:30 |
I-48 Daniel Glazar
A simulation-based sample size analysis of a joint model of longitudinal and survival data for patients with glioma
Wednesday 10:00-11:30 |
I-49 Xiaohua Gong
Pharmacometric Analysis in Support of Dose Optimization for Pemigatinib Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangements
Wednesday 10:00-11:30 |
I-50 Sebastiaan Goulooze
Conditional overall survival (OS) simulations with a joint tumor size (TS)-OS model to support oncology development decision making
Wednesday 10:00-11:30 |
I-52 Jinju Guk
Integration of early circulating tumour DNA (ctDNA) changes into tumour growth inhibition modelling.
Wednesday 10:00-11:30 |
I-56 Jennifer Hibma
Population Pharmacokinetic Analysis of Elranatamab in Patients with Multiple Myeloma
Wednesday 10:00-11:30 |
I-59 Itziar Irurzun Arana
Population PK modelling of camizestrant, a next-generation oral selective estrogen receptor degrader, as monotherapy and in combination with palbociclib in ER+/HER2- advanced breast cancer
Wednesday 10:00-11:30 |
I-67 Huub Jan Kleijn
Population Pharmacokinetic Analysis of PD-L1 Checkpoint Inhibitor Cosibelimab in Subjects with Advanced Cancers
Wednesday 10:00-11:30 |
I-68 Fenja Klima
Separating out multi-analyte endoxifen measurements: Derivation of a conversion factor to enable assessment of analytically heterogeneous clinical trial data
Wednesday 10:00-11:30 |
I-88 Elena Tosca
Predicting tumor volume doubling time and progression-free survival curves in cancer patients from patient-derived-xenograft (PDX) models: a translational model-based population approach
Wednesday 10:00-11:30 |
I-89 Mira Tout
A translational minimal physiologically-based pharmacokinetic (mPBPK) model to predict preclinical and clinical PK of MEN1703 in tissues
Wednesday 10:00-11:30 |
I-91 Lisa van der Heijden
Quantification of the difference in oral docetaxel pharmacokinetics in patients with prostate cancer compared to patients with other solid tumours
Wednesday 10:00-11:30 |
I-95 Anyue Yin
Population pharmacokinetics and toxicity analysis of high-dose methotrexate in patients with central nervous system lymphoma
Wednesday 10:00-11:30 |
I-96 Seok Kyue Yoon
Disease progression modeling analysis of the change of bone mineral density by postoperative hormone therapies in postmenopausal patients with early breast cancer
Wednesday 10:00-11:30 |
III-10 Summer Feng
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin
Thursday 10:15-11:45 |
III-25 Marie Lambert
Population pharmacokinetic model to assess bone marrow absorbed dose after 177Lu-Dotatate administration
Thursday 10:15-11:45 |
III-28 Félicien Le Louedec
Model-informed precision dosing of high-dose IV busulfan in Thai pediatric patients
Thursday 10:15-11:45 |
III-29 Félicien Le Louedec
Model-informed precision dosing of protein kinase inhibitors: benefits and limits. The example of imatinib.
Thursday 10:15-11:45 |
III-32 Apolline Lefevre
A mechanistic PK/PD model to predict cytokine release and tumor cell killing associated to T-cell bispecific therapies
Thursday 10:15-11:45 |
III-39 Sarah Lobet
Influence of body composition on the pharmacokinetics of monoclonal antibodies : example of cetuximab and bevacizumab
Thursday 10:15-11:45 |
III-41 Aurelie Lombard
Exploring the use of constant and time-varying observation-based versus model-based tumour size metrics for early predictions of drug efficacy on overall survival in malignant pleural mesothelioma
Thursday 10:15-11:45 |
III-43 Vincent Madelain
Impact of interaction model choice in PKPD analysis evaluating drug combination in TGI in vivo studies
Thursday 10:15-11:45 |
III-52 Mourad Mseddi
Population pharmacokinetics of abiraterone in patients with metastatic castration resistant prostate cancer
Thursday 10:15-11:45 |
III-53 Ida Neldemo
Application of tumor size modelling and simulations to support the dose selection of BI 907828 for a Phase II study
Thursday 10:15-11:45 |
III-58 Theodoros Papathanasiou
Population pharmacokinetics of belantamab mafodotin in relapsed or refractory multiple myeloma patients with severe renal impairment
Thursday 10:15-11:45 |
III-60 Antoine Pitoy
Contribution of modelling jointly progression-free survival and biomarker longitudinal data for therapeutic evaluation in oncology
Thursday 10:15-11:45 |
III-62 Alicja Puszkiel
Nivolumab de-escalation in patients with complete response: model-based simulations of alternative dosing regimens and noninferiority clinical trials
Thursday 10:15-11:45 |
III-65 Pascale Rietveld
Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin
Thursday 10:15-11:45 |
III-66 Maša Roganović
Modelling fatigue events in prostate cancer patients on radiotherapy
Thursday 10:15-11:45 |
III-67 Davide Ronchi
Model-based analysis of patient-derived organoids for evaluating anticancer drugs
Thursday 10:15-11:45 |
III-68 Alberto Russu
Population pharmacokinetic modeling and bioequivalence clinical trial simulations of niraparib plus abiraterone acetate administered as single-agent combination and dual-acting tablets plus prednisone for the treatment of metastatic castration-resistant prostate cancer
Thursday 10:15-11:45 |
III-71 Javier Sanchez Fernandez
Building evidence on the PKPD relationship with bispecific co-stimulatory antibodies using in vitro data: FAP-4-1BBL example
Thursday 10:15-11:45 |
III-72 Aymara Sancho
Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: the interplay between cancer cells and components of the tumor microenvironment.
Thursday 10:15-11:45 |
III-75 Emilie Schindler
Population PK-PD modeling and exposure-response analysis in multiple myeloma patients treated with intravenous forimtamig, a T-cell engaging 2:1 bispecific antibody targeting GPRC5D and CD3
Thursday 10:15-11:45 |
III-76 Miriam Schirru
A QSP model for predicting efficacy assessment of combined treatment of radiotherapy and anti-PD-1 for NSCLC patients through virtual clinical trials.
Thursday 10:15-11:45 |
III-77 Alejandro Serrano Alcaide
Application of an immune-oncology framework to explore the role of regulatory T cells in antitumor response.
Thursday 10:15-11:45 |
III-79 Hinke Siebinga
Optimizing radionuclide therapy with 177Lu-HA-DOTATATE in patients with neuroendocrine tumors using semi-physiological population PK models
Thursday 10:15-11:45 |
III-82 Tomás Sou
Population PK/PD modelling of platelet dynamics for dose selection in patients with haematological malignancies
Thursday 10:15-11:45 |
III-84 Herbert Struemper
Development of a joint tumor size (TS)–overall survival (OS) modelling and simulation (M&S) framework supporting oncology development decision making
Thursday 10:15-11:45 |
III-86 Zhiyuan Tan
Population pharmacokinetic analysis of pazopanib in adult patients with metastatic renal cell carcinoma and soft tissue sarcoma
Thursday 10:15-11:45 |
III-87 David Ternant
A multi drug disposition model accounting for rituximab antigen binding portion (Fab) and crystallizable (Fc) mediated drug disposition mechanisms
Thursday 10:15-11:45 |
